Celgene expands collaboration with Evotec

11 October 2018
2019_biotech_test_vial_discovery_big

German biotech Evotec (EVT: Xetra) today revealed that it will receive a $6 million payment from Celgene (Nasdaq: CELG) following Celgene's decision to expand the collaboration to include additional cell lines.

Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients' symptoms and there is a huge unmet medical need for therapeutic modalities that slow down or reverse disease progression. The collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging Evotec's unique human induced pluripotent stem cell (iPSC) technology platform, which is one of the largest and most sophisticated platforms in the industry.

"This achievement is the latest example of the performance of our scientists and reflects continuous investment to enhance and expand Evotec's iPSC platform. We are confident that the extended portfolio provides additional opportunities for further research into disease-modifying treatments which will ultimately benefit patients suffering from neurodegenerative conditions," said Dr Cord Dohrmann, chief scientific officer of Evotec.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology